

Demyelinating Neurological Adverse Events Following the Use of Anti TNF- α Agents, A Double-Edged Sword-Case Report

Miral Hamed Gharib^{1*}, Beatriz Garcia-Canibano², Dirk Theophiel O. Deleu², Mohamed Awni AL Kahlout¹, Hani Malallah AL Essa¹, Samar AL Emadi¹

¹Rheumatology, Department of Medicine, Hamad medical corporation, Qatar

²Neurology, Department of Medicine, Hamad General Hospital, Qatar

*Corresponding author: Dr. Miral Hamed Gharib, Consultant, Rheumatology Hamad medical corporation.

Citation: Gharib MH, Canibano BG, Deleu DTO, AL Kahlout MA, AL Essa HM, et al. (2021) Demyelinating Neurological Adverse Events Following the Use of Anti TNF- α Agents, A Double-Edged Sword-Case Report. Annal Cas Rep Rev: ACRR-290.

Received Date: 08 November, 2021; **Accepted Date:** 16 November, 2021; **Published Date:** 22 November, 2021

Abstract

Background: Tumor necrosis factor antagonists (anti-TNF α) are an established therapeutic option for several autoimmune and inflammatory bowel diseases. Despite their clinical effectiveness, neurological adverse events have been reported and literature data suggest a potential role of anti-TNF α in the induction of demyelination.

Case presentation: In this series, we present three cases of demyelination after the use of anti-TNF- α agents. The first case involved a 21-year-old man with HLA-B27 negative peripheral spondylarthritis who had been taking adalimumab for 2 years; He developed headache, urinary incontinence, and bilateral lower extremity numbness that progressed to the middle of the trunk for 2 days. Magnetic resonance imaging (MRI) showed multiple hyperintense enhancement lesions in the left paramedian anterior pons consistent with multiple sclerosis (MS). The second case included a 17-year-old woman, who was on 2 years of adalimumab treatment for juvenile idiopathic arthritis and chronic anterior uveitis, who developed new-onset dizziness and tremors. The clinical examination showed signs of cerebellar dysfunction. MRI findings were consistent with multiple sclerosis. The third case was a 34-year-old male who was on 5 years of Infliximab treatment for ankylosing spondylitis when he developed left-hand numbness and weakness. Cerebrospinal fluid (CSF) analysis and MRI findings were consistent with demyelination. Discontinuation of adalimumab in all patients resulted in the resolution of the symptoms with no recurrence over the next 18 months in the first two cases but there were two recurrent attacks in the third one.

Conclusion: Despite the small number of patients, our series adds to the growing body of evidence supporting a causal link between anti-TNF- α agents and demyelination. Thus, we can conclude that on suspicion of any neurological side effects, early discontinuation of the TNF-alpha blockers and requesting urgent MRI scan to confirm the diagnosis is of utmost importance.

Keywords: Tumor necrosis factor antagonists, Demyelination, Multiple sclerosis.

Introduction

Tumor necrosis factor- α (TNF α) is a pleiotropic cytokine that plays a key role in host defense mechanisms and exhibits multifunctional proinflammatory properties. [1] It was found that the pathogenesis of many diseases, including rheumatoid arthritis, Crohn's disease, atherosclerosis, psoriasis, sepsis, diabetes, and obesity, has been associated with aberrant TNF- α development and TNF receptor signaling. Therefore, TNF- α and its receptor were proposed as a therapeutic target in the treatment of many diseases. [2] With great success in terms of efficacy and safety, anti-TNF- α agents have revolutionized the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis,

juvenile polyarticular rheumatoid arthritis, and inflammatory bowel disease. These agents act by abrogating the soluble TNF α , thus preventing its binding on TNFR1/TNFR2 receptors [3,4]. Currently, many anti-TNF- α agents have been licensed for treating certain inflammatory diseases including rheumatoid arthritis and inflammatory bowel disease. However, these agents are not without side effects. Aside from the usual presumed infectious difficulties, uncommon cases of neuroinflammatory demyelinating disorders, such as multiple sclerosis (MS), myelitis, and optic neuritis, have been documented with the use of anti-TNF- α . [5].

In our institution, anti-TNF- α agents such as infliximab, adalimumab, and etanercept, have been used widely specially in the treatment of rheumatoid arthritis,

ankylosing spondylitis, and inflammatory bowel disease. However, their increasing use has revealed a variety of adverse events. We reported three cases of demyelination following the use of anti-TNF- α . The cases were diagnosed with MS based on McDonald's criteria (2017) for the diagnosis of Multiple Sclerosis. [6] These cases were aimed at increasing the physician's awareness of the demyelinating adverse effect associated with anti-TNF- α therapy.

Case presentation

Case 1: A 21-year-old Qatari gentleman was on adalimumab for HLA-B27 negative peripheral spondyloarthritis. After being kept on adalimumab for 2 years, he developed severe headache, urinary

incontinence, and bilateral lower limb numbness, which progressed towards the middle of the trunk for several days. The neurological examination uncovered dysesthesias below the dermatome T4 associated with brisk tendon reflexes, while the remainder of the examination was normal. The diagnosis of multiple sclerosis (MS) was established by the presence of multiple hyperintense lesions on brain MRI in the left paramedian anterior pons, the left posterolateral medulla, and bilateral periventricular white matter, some of them involving the optic radiations. Similar lesions were identified in the right lateral aspect of corpus callosum splenium, and in the cervical spinal cord at the level of C2-C3 level and a small area of T2 hyperintensity in the thoracic spinal cord at the T5 level as shown in figure 1 (A,B,C,D). There was no family history of MS.




Figure1: (A) There are few small foci of T2 and FLAIR hyperintensity noted in the periventricular white matter (bilaterally), perpendicular to the ventricular margin. (B) There is a small area of T2 and FLAIR hyperintensity noted in the left paramedian anterior pons. (C, D) There is a small area of T2 hyperintensity with corresponding post-contrast enhancement noted in the cervical spinal cord at C2-C3 level.

Complete resolution of neurological symptoms due to discontinuation of adalimumab was observed within one month. However, he developed abdominal pain with loose bloody motions, in which Ilio-colonoscopy and biopsy confirmed the diagnosis of Crohn's disease. Remarkably, we found that he had a significant family ancestry of inflammatory bowel disease. His inflammatory bowel disease and peripheral arthritis were well-controlled on ustekinumab (IL12/23 inhibitor) and a one-year follow-up showed no relapses.

Case 2: A 19-year-old Qatari woman, who was on adalimumab for juvenile idiopathic arthritis and chronic anterior uveitis for 2 years; developed new-onset dizziness and hand tremors. Neurological examination

showed impaired cerebellar function as evidenced by intention tremors, ataxia, dysmetria, and dysdiadochokinesia with normal tone, power, and sensation, reflexes were less brisk. She had no history of multiple sclerosis. MRI revealed multiple hyperintense white matter lesions especially in bilateral cerebellar peduncles, periventricular, subcortical and juxtacortical, brain stem, corpus callosum, and left anterior thalamus, also multiple patchy T2 hyperintensities noted in the cervical and mid-thoracic spinal cord with foci of enhancement noted in the mid-thoracic spinal cord, in keeping with active lesions as shown in figure 2 (A, B). Her CSF analysis revealed the presence of CSF unique oligoclonal bands.




Figure 2: (A) There are multiple periventricular, subcortical and juxtacortical white matter foci of T2 and FLAIR hypersignal in both cerebral hemispheres, brain stem, bilateral middle cerebellar peduncles, corpus callosum and left anterior thalamus. (B) There is focal enhancement noted in the left peritrigonal white matter lesion.

Discontinuation of adalimumab resulted in near-complete improvement in her symptoms and she was shifted to methotrexate with good control of her arthritis and uveitis. She subsequently switched to rituximab to control her arthritis and demyelinating disease. After a year of follow-up, she recovered without having any further relapses.

Case 3: A 34-year-old man was diagnosed with ankylosing spondylitis 7 years ago. He was initially treated with sulfasalazine and nonsteroidal anti-inflammatory drugs. After two years he was started on

infliximab to control his disease activity. Five years after infliximab initiation, he developed unexplained left-hand numbness and weakness. A diagnosis of multiple sclerosis was made based on MRI findings, which showed numerous bilateral variable-sized, different-shaped plaques of high signal intensity on T2WI/ FLAIR involving mainly in the brain and spinal cord associated with left deep periventricular frontal and left cerebellar peduncle enhanced plaques as shown in figure 3 (A,B,C,D,E). The cerebrospinal fluid revealed oligoclonal, while the rest of the parameters were within the normal limits.




Figure 3: (A, B) There are at least 2 definite high signal intensity plaques on the sagittal T2W1 are seen at D6-7, D9-10 levels (arrow). (C,D) Numerous bilateral variable-sized, different shaped plaques of high signal intensity on T2W1/FLAIR are seen mainly in the deep white matter at periventricular location and centrum semiovale, perpendicular callososeptal lesions, cerebellar peduncles, and cerebellar white matter. (E) Incomplete ring enhancement lesions are seen in the left deep periventricular frontal lobe and left cerebellar peduncle.

Infliximab was discontinued and he received IV pulse dose steroid for five days with complete recovery of his symptoms, but two years later he developed another attack with diplopia, left leg numbness, and weakness followed by a third attack 4 years later consisting of left facial numbness. Each attack was treated with pulse dose steroids 1 g for 5 days with complete recovery. He was kept on NSAIDs for his ankylosing spondylitis and was recommended to start rituximab as a disease-modifying treatment to control multiple sclerosis.

Discussion

The development of CNS demyelination with anti-TNF- α therapy has been shown in several reports from various countries. [5,7,8] It is unclear, however, whether these demyelinating events are coincidental or whether they are causally associated with the use of TNF- α antagonists [7]. Clinical trials of TNF- α blockers in patients with MS that showed an increase in demyelinating events [9], in addition to the complete remission of symptoms after withdrawal of this agent, [5,7] and temporal relation, as well as the rechallenge phenomenon that was demonstrated in many cases, [10-13] favor a causal association.

On the other hand, one wonders whether this correlation is simply the unmasking of a pre-existing MS or the onset of new demyelinating diseases [5,7,8]. Interestingly, some authors identified the demyelination of CNS in asymptomatic patients before the initiation of anti-TNF α therapy, which suggests that TNF- α blockers may unmask pre-existing MS as well as provoking new-onset demyelination [5].

The mechanisms underlying demyelination predisposition or demyelination exacerbation in patients treated with anti-TNF- α agents are not fully understood and several theories have been suggested. One of these theories is called lack of entry theory, which suggests that TNF- α blockers cannot penetrate the intact blood-brain barrier (BBB) to suppress demyelination but they can enhance demyelination through increased ingress of peripheral autoreactive T-cells into the CNS [8]. This theory provides a possible explanation for the failure of anti-TNF- α blockers in reducing demyelination and for their effect on aggravating MS. However, they cannot adequately explain the new onset of demyelination, as in our cases.

The time between exposure to TNF- α blockers and the onset of symptoms varies widely between different reports. In the report by Kemanetzoglou et al, [8] the time between exposure to TNF- α blockers and the onset of symptoms ranged between 3 days and 6 years, while Mohan et al [11] found that the time between exposure to the onset of symptoms was between 1 week and 15 months. As noted in our series, the time between the initiation of TNF- α blocker and the development of symptoms ranged between 2 years as in cases 1 and 2 and 5 years as in case 3, which falls within the range of 3 days to 6 years that was mentioned above.

As noted in our series and other reports, [5,7,8] the discontinuation of the TNF α blockers led to a complete remission of symptoms. Relapses of demyelination after remission have been reported by many authors [14,15] as well as in case 3 of our series, which could be explained by the common spontaneous relapsing-remitting episodes of MS. However, despite discontinuation of treatment, demyelination disorders may persist, indicating that anti-TNF- α agents may activate the demyelination mechanism, which further develops independently. [15]. Another question to be answered is whether demyelination during anti-TNF α agents actually meets the criteria for MS diagnosis or whether it constitutes a different MS-like syndrome. From our study, it is recommended to avoid the use of Anti -TNF α blockers in patients with own history or family history of MS or any other demyelinating disease. And in case of development of any new neurological symptoms, the patient needs a thorough neurological examination, and once demyelination is confirmed, Anti-TNF blockers should be withdrawn. In addition to those with a family history of demyelination, those with a family history of the autoimmune disease might also be at higher risk of developing demyelinating events as in our first case.

Conclusion

Despite the small number of patients, our series adds to the growing body of evidence supporting a causal link between anti-TNF- α agents and demyelination, which clinicians should be aware of. On expectation of any neurological side effects, early discontinuation of the TNF- α blockers and requesting urgent MRI scan to confirm the diagnosis is of utmost importance.

Abbreviations:

Tumor necrosis factor antagonists (anti-TNF α)
Magnetic resonance imaging (MRI)
multiple sclerosis (MS)
Cerebrospinal fluid (CSF)
blood-brain barrier (BBB)

Ethics approval and consent to participate

Not applicable

Consent for publication

Written informed consent was obtained from the participants

Availability of data and materials

Not applicable

Competing interests

"The authors declare that they have no competing interests"

Funding

This case report is not funded

Acknowledgements

Not applicable

References

1. Silva LB, Neto AP, Maia SM, Guimarães CD, Quidute IL, Carvalho A, Júnior SA, Leão JC. The Role of TNF- α as a Proinflammatory Cytokine in Pathological Processes. *The Open Dentistry Journal* 2019; 13: 332-338.
2. Parameswaran N, Patial S. Tumor necrosis factor- α signaling in macrophages. *Crit Rev Eukaryot Gene Expr*. 2010;20:87-103.
3. Lin J, Ziring D, Desai S, et al. TNF α blockade in human diseases: an overview of efficacy and safety. *Clinical Immunology*. 2008;126(1):13-30.
4. Karampetsou MP, Liossis SNC, Sfikakis PP. TNF- α antagonists beyond approved indications: stories of success and prospects for the future. *QJM*. 2010;103(12):917-928.
5. Kaltsonoudis E, Zikou AK, Voulgari PV, Konitsiotis S, Argyropoulou MI, Drosos AA. Neurological adverse events in patients receiving anti-TNF therapy: a prospective imaging and electrophysiological study. *Arthritis Res Ther*. 2014;16(3):R125. doi:10.1186/ar4582.
6. Thompson AJ, Banwell BL, Barkhof F et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. *Lancet Neurol*. 2018 Feb;17(2):162-173.
7. Andreadou E, Kemanetzoglou E, Brokalaki Ch, et al. Demyelinating Disease following Anti-TNF α Treatment: A Causal or Coincidental Association? Report of Four Cases and Review of the Literature. *Case Rep Neurol Med*. 2013;2013:671935. doi:10.1155/2013/671935.
8. Kemanetzoglou E, Andreadou E. CNS Demyelination with TNF- α Blockers. *Curr Neurol Neurosci Rep*. 2017 Apr;17(4):36. doi: 10.1007/s11910-017-0742-1.
9. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. *Neurology*. 1999 Aug 11;53(3):457-65.
10. Kim A, Saffra N. A case report of adalimumab-associated optic neuritis. *J Ophthalmic Inflamm Infect*. 2012;2(3):145-7.
11. Mohan N, Edwards ET, Cupps TR, Oliverio PJ, Sandberg G, Crayton H, Richert JR, Siegel JN. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. *Arthritis Rheum*. 2001;44:2862-9.
12. Tanno M, Nakamura I, Kobayashi S, Kurihara K, Ito K. New onset demyelination induced by infliximab therapy in two rheumatoid arthritis patients. *Clin Rheumatol*. 2006;25(6):929-33.
13. Gomez-Gallego M, Meca-Lallana J, Fernandez-Barreiro A. Multiple sclerosis onset during etanercept treatment. *Eur Neurol*. 2008;59(1-2):91-3.
14. Fernández-Espartero MC, Pérez-Zafrilla B, Naranjo A, Esteban C, Ortiz AM, Gómez-Reino JJ, et al. Demyelinating disease in patients treated with TNF antagonists in rheumatology: data from BIOBADASER, a pharmacovigilance database, and a systematic review. *Semin Arthritis Rheum*. 2011 Feb;40(4):330-7.
15. Seror R, Richez C, Sordet C, Rist S, Gossec L, Direz G, Houvenagel E, Berthelot JM, Pagnoux C, Dernis E, Melac-Ducamp S, Bouvard B, Asquier C, Martin A, Puechal X, Mariette X; Club Rhumatismes et Inflammation Section of the SFR. Pattern of demyelination occurring during anti-TNF- α therapy: a French national survey. *Rheumatology (Oxford)*. 2013 May;52(5):868-74.